Regulacje i polityka gospodarcza · 15/11/2004

FDA Withdraws Proposed Rules for Evaluating Hematological Disorders

The FDA is withdrawing its proposed rules for evaluating hematological disorders due to public comments raising significant issues, and plans to publish new rules at a later date, while finalizing rules for malignant neoplastic diseases.